(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 November 2006 (09.11.2006)

PCT

(10) International Publication Number
WO 2006/117552 A1

(51) International Patent Classification:
C07D 215/22 (2006.01) *C07D 239/94* (2006.01)
C07D 417/12 (2006.01) *C07D 403/12* (2006.01)
C07D 215/36 (2006.01) *C07D 409/12* (2006.01)
C07D 215/42 (2006.01) *C07D 413/12* (2006.01)
C07D 401/12 (2006.01) *A61K 31/435* (2006.01)
C07D 215/44 (2006.01) *A61K 31/495* (2006.01)
C07D 239/90 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/GB2006/001609

(22) International Filing Date: 4 May 2006 (04.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0509227.5 5 May 2005 (05.05.2005) GB

(71) Applicant *(for all designated States except US)*: **CHROMA THERAPEUTICS LTD** [GB/GB]; 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DAVIDSON, Alan, Hornsby** [GB/GB]; Chroma Therapeutics Limited, 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DAVIES, Stephen, John** [GB/GB]; Chroma Therapeutics Limited, 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **MOFFAT, David, Festus, Charles** [GB/GB]; Chroma Therapeutics Limited, 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(74) Agent: **WALLS, Alan, James**; PO Box 223, Tadworth, Surrey KT20 5YF (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY




(IA)



(IB)



(X)



(Y)

(57) **Abstract:** Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y^1, L^1 and z are as defined in the claims; R_6 is C_1-C_4alkoxy, hydrogen or halo; W represents a bond, $-CH_2-$, -O-, -S-, $-S(=O)_2-$, or $-NR_5-$ where R_5 is hydrogen or C_1-C_4 alkyl; Q is =N-, =CH- or $=C(X^1)-$ wherein X^1 is cyano, cyclopropyl or halo; linker radicals L^2 are as defined in the claims; R is a radical of formula (X) or (Y): wherein R_1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R_4 is hydrogen; or optionally substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, aryl, aryl(C_1-C_6 alkyl)-, heteroaryl, heteroaryl(C_1-C_6 alkyl)-, $-(C=O)R_3$, $-(C=O)OR_3$, or $-(C=O)NR_3$ wherein R_3 is hydrogen or optionally substituted (C_1-C_6)alkyl, C_3-C_7 cycloalkyl, aryl, aryl(C_1-C_6 alkyl)-, heteroaryl, or heteroaryl(C_1-C_6 alkyl)-; R_4' is hydrogen or optionally substituted C_1-C_6 alkyl; and D is a monocyclic heterocyclic ring of 5 or 6 ring atoms.

WO 2006/117552 A1